Vancomycin in the Target Site Treatment of Intracranial Infection

Vancomycin in the Target Site Treatment of Intracranial Infection : a New Strategy for PK/PD Treatment

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03585426

Enrollment

Registered

2018-07-13

Start date

2016-03-31

Completion date

2018-12-31

Last updated

2018-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vancomycin

Brief summary

Vancomycin, a novel intravenously administered antibiotic, currently plays a key role in the management of complicated multi-organism infections. However,current LC-MS/MS methods briefly describe parameters and the only reported internal standard was sometimes difficult to obtain. In our study,an updated LC-MS/MS method for the quantitative analysis of vancomycin in human serum was developed.

Interventions

DRUGVancomycin

Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

In ICU; ventricle drainage was carried out; renal function is normal, namely creatinine clearance rate is \>60ml/min;

Exclusion criteria

women in pregnancy or lactation;in patients with renal insufficiency, the creatinine clearance rate (Clcr) is less than 60ml/min.

Design outcomes

Primary

Measure	Time frame	Description
Vancomycin concentration change in serum and cerebrospinal fluid	0.5h, 1h, 1.5h, 3h, 5h, 7h, 9h, and 12h after treatment	Quantitative analysis of vancomycin in serum and cerebrospinal fluid after treatment by an updated LC-MS/MS method.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026